ADMA Biologics

Focus: ADMA Biologics is a biotechnology company focused on immune globulin therapies for infectious diseases and respiratory conditions. The company operates as a mid-cap biotech with a specialized pipeline in biologics.

Infectious Diseases Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About ADMA Biologics

AI assessmentNot Hiring

No open roles listed right now. Follow ADMA Biologics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Bivigam

Primary Immune Deficiency Disorder

N/A

Clinical Trials (1)

NCT03037359A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

N/A

Help build intelligence for ADMA Biologics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline focused on unmet needs in primary immune deficiency and respiratory infections with multiple Phase 3/4 programs advancing toward commercialization
Specialized focus on immune globulin biologics offers deep technical expertise in a niche but defensible therapeutic area
Multiple Phase 4 programs indicate potential for rapid market entry and revenue generation

Watch Out For

Zero active job openings signals either stable headcount, hiring freeze, or limited growth trajectory
No financial data available (revenue, R&D spend, cash position) makes it difficult to assess company stability and restructuring risk

Generated by Claude from ADMA Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Hepatitis C Immune Globulin Intravenous (Human)

Transplantation Infection

Phase 2

Immune Globulin Intravenous (Human)

Respiratory Syncytial Virus Infection

Phase 2

RI-001

Upper Respiratory Tract Infection

Phase 2

Clinical Trials (1)

NCT00632463RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

Phase 2

RI-002

Primary Immune Deficiency Disorder

Phase 3

Clinical Trials (1)

NCT01814800Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Phase 3

Immune Globulin Intravenous (Human)

Primary Immune Deficiency Disorder

Phase 3

Clinical Trials (2)

NCT00538915Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Phase 3

NCT00473824Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

Phase 2

Immune Globulin Intravenous (Human)

Primary Immune Deficiency Disorders

Phase 3

Immune Globulin Intravenous (Human)

Primary Immune Deficiency

Phase 4

Immune Globulin Intravenous (Human)

Primary Immune Deficiency Disorder

Phase 4

Bivigam

Humoral Immune Response

Phase 4

Clinical Trials (1)

NCT03164967Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Phase 4

Asceniv™

Primary Immune Deficiency

Phase 4

Clinical Trials (1)

NCT05070455An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Phase 4